Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic microorganisms in the gut lumen refer to a diverse group of bacteria, viruses, and parasites that colonize the gastrointestinal tract and cause disease through mechanisms such as toxin secretion, mucosal invasion, and competition with commensal flora. Common bacterial examples include Clostridioides difficile, which often proliferates following antibiotic-induced dysbiosis, and enteric pathogens like Salmonella and Shigella species (StatPearls, 2023). These organisms disrupt intestinal homeostasis, leading to symptoms ranging from mild diarrhea to severe, life-threatening colitis (NIH, 2022). Therapeutic management typically involves the use of antimicrobial agents like Rifaximin, which acts locally within the gut lumen due to its poor systemic absorption, or targeted antibiotics like Vancomycin and Fidaxomicin (PubChem, 2024). Emerging treatments also include probiotics and fecal microbiota transplantation (FMT), which aim to restore a healthy microbial balance and outcompete pathogens to prevent recurrence.
Antimicrobial agents target these microorganisms by inhibiting bacterial cell wall synthesis, disrupting protein synthesis via ribosomal binding, or interfering with DNA/RNA replication. Non-antibiotic approaches involve competitive exclusion by beneficial microbes or the neutralization of microbial toxins.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic microorganisms in the gut lumen.